Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome

American Journal of Gastroenterology

Volumn 96, Issue 9 SUPPL., 2001, Pages 2662-2670

  Lembo, Tony ^b   Wright, Richard A ^b   Bagby, Barbara ^b   Decker, Chris ^b   Gordon, Susan ^b   Jhingran, Priti ^b   Carter, Eric ^a  

^a GLAXOSMITHKLINE   (United States)

^b North American Medical Affairs ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON;

ADULT; ARTICLE; CHOLECYSTITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; MAJOR CLINICAL STUDY; MIGRAINE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

CARBOLINES; COLONIC DISEASES, FUNCTIONAL; DIARRHEA; FEMALE; HUMANS; MIDDLE AGED; SEROTONIN ANTAGONISTS;

EID: 0034827794     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)02690-9     Document Type: Article

References (35)

1. Functional bowel disorders and functional abdominal pain
2. Irritable bowel syndrome: A technical review for practice guideline development
3. Epidemiology of irritable bowel syndrome in the United States
4. A national survey of practice patterns of gastroenterologists with comparison to the past two decades
5. Irritable bowel syndrome in general practice: Prevalence, characteristics and referrals
6. Urgency as an endpoint in IBS
7. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom
8. The impact of IBS on health-related quality of life
9. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact
10. A national survey of IBS in females: Physician and patient perspectives
11. Alosetron, a 5HT3 receptor antagonist, in the treatment of non-constipated female IBS patients
12. Improvement in pain and bowel function in female irritable bowel syndrome patients with alosetron, a 5-HT3-receptor antagonist
13. The efficacy and safety of alosetron in female patients with irritable bowel syndrome: A randomised, placebo controlled study
14. Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
15. Use of a novel electronic data collection system in multicenter studies of irritable bowel syndrome
16. On the combination of independent two sample tests of Wilcoxon
17. A simple sequentially rejective multiple test procedure
18. Clinical economics review: Irritable bowel syndrome
19. Design of treatment trials for functional gastrointestinal disorders
20. Irritable bowel syndrome clinical trial design: Future needs
21. Adequate relief as an endpoint in clinical trials in irritable bowel syndrome
22. Validation of adequate relief as an endpoint in irritable bowel syndrome
23. Problems and challenges in the design of irritable bowel syndrome clinical trials: Experience from published trials
24. 5-HT (serotonin) physiology and related drugs
25. Roles played by 5-hydroxytryptamine in the physiology of the bowel
26. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
27. Alosetron, a 5-HT-3 receptor antagonist, delays colonic transit in patients with IBS, and healthy volunteers
28. 3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: A segmental perfusion study
29. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients
30. Ischemic lesions of the bowel
31. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist
32. Patient satisfaction with Lotronex (alosetron HCl) treated nonconstipated irritable bowel syndrome (IBS) females
33. Impact of Lotronex on workplace productivity and activity time in females with non-constipated IBS